{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:29:55Z","timestamp":1792877395313,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.riam.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T19:22:38Z","timestamp":1742671358000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of current clinical guidelines on the management of invasive fungal disease"],"prefix":"10.1016","volume":"42","author":[{"given":"Santiago","family":"de Cossio Tejido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-2124","authenticated-orcid":false,"given":"Miguel","family":"Salavert Llet\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2025.02.002_bib0205","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37201\/req\/013.2023","article-title":"Recommendations on the use of azole antifungals in hematology\u2013oncology patients","volume":"36","author":"Azanza","year":"2023","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.riam.2025.02.002_bib0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1055\/s-0039-1698429","article-title":"Current concepts in the epidemiology, diagnosis, and management of histoplasmosis syndromes","volume":"41","author":"Azar","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.riam.2025.02.002_bib0215","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study","volume":"72","author":"Bose","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 7","key":"10.1016\/j.riam.2025.02.002_bib0220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imj.15592","article-title":"Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology\/oncology setting, 2021","volume":"51","author":"Bupha-Intr","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.riam.2025.02.002_bib0225","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00134-011-2344-8","article-title":"Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis","volume":"37","author":"Burghi","year":"2011","journal-title":"Intensive Care Med"},{"issue":"S7","key":"10.1016\/j.riam.2025.02.002_bib0230","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/imj.15590","article-title":"Consensus guidelines for the diagnosis and management of cryptococcosis and rare yeast infections in the haematology\/oncology setting, 2021","volume":"51","author":"Chang","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.riam.2025.02.002_bib0235","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S1473-3099(21)00203-6","article-title":"Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"21","author":"Chen","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2025.02.002_bib0240","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/myc.12778","article-title":"Isavuconazole for treatment of rare invasive fungal diseases","volume":"61","author":"Cornely","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2025.02.002_bib0245","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 7","key":"10.1016\/j.riam.2025.02.002_bib0250","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.riam.2025.02.002_bib0255","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2025.02.002_bib0260","doi-asserted-by":"crossref","first-page":"e0120370","DOI":"10.1371\/journal.pone.0120370","article-title":"Causes of death in a contemporary cohort of patients with invasive aspergillosis","volume":"10","author":"Garcia-Vidal","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.riam.2025.02.002_bib0265","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eimc.2018.03.018","article-title":"Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 update by the GEMICOMED-SEIMC\/REIPI","volume":"37","author":"Garcia-Vidal","year":"2019","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"10.1016\/j.riam.2025.02.002_bib0270","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.riam.2025.02.002_bib0275","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1128\/AAC.00850-13","article-title":"Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii","volume":"57","author":"Hazirolan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2025.02.002_bib0280","doi-asserted-by":"crossref","first-page":"e3727","DOI":"10.1093\/cid\/ciaa1555","article-title":"Voriconazole versus itraconazole for the initial and step-down treatment of histoplasmosis: a retrospective cohort","volume":"73","author":"Hendrix","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2025.02.002_bib0285","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.riam.2025.02.002_bib0290","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2025.02.002_bib0295","doi-asserted-by":"crossref","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Husain","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.riam.2025.02.002_bib0300","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/myc.13622","article-title":"A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections","volume":"66","author":"Kato","year":"2023","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2025.02.002_bib0305","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jac\/dkz050","article-title":"Isavuconazole brain penetration in cerebral aspergillosis","volume":"74","author":"Lamoth","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2025.02.002_bib0310","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.riam.2025.02.002_bib0315","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.riam.2025.02.002_bib0320","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.riam.2025.02.002_bib0325","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2025.02.002_bib0330","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/myc.12777","article-title":"Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species","volume":"61","author":"Marty","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2025.02.002_bib0335","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.riam.2025.02.002_bib0340","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.riam.2025.02.002_bib0345","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2025.02.002_bib0350","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/cid\/ciy406","article-title":"Breakthrough fungal infections in patients with leukemia receiving isavuconazole","volume":"67","author":"Rausch","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2025.02.002_bib0355","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats","volume":"61","author":"Schmitt-Hoffmann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2025.02.002_bib0360","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s15010-011-0108-6","article-title":"The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis","volume":"39","author":"Schwartz","year":"2011","journal-title":"Infection"},{"key":"10.1016\/j.riam.2025.02.002_bib0365","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/mmy\/myz103","article-title":"Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system","volume":"58","author":"Schwartz","year":"2020","journal-title":"Med Mycol"},{"key":"10.1016\/j.riam.2025.02.002_bib0370","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study","volume":"81","author":"Singh","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.riam.2025.02.002_bib0375","doi-asserted-by":"crossref","first-page":"e253718","DOI":"10.1136\/bcr-2022-253718","article-title":"Disseminated histoplasmosis in an immunosuppressed patient successfully treated with isavuconazole","volume":"16","author":"Sircar","year":"2023","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.riam.2025.02.002_bib0380","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkp138","article-title":"In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species","volume":"64","author":"Thompson","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2025.02.002_bib0385","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S1473-3099(21)00191-2","article-title":"Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology","volume":"21","author":"Thompson","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2025.02.002_bib0390","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.riam.2025.02.002_bib0395","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2025.02.002_bib0400","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140625000178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140625000178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:25:50Z","timestamp":1752575150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140625000178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1130140625000178"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2025.02.002","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of current clinical guidelines on the management of invasive fungal disease","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Asociaci\u00f3n Espa\u00f1ola de Micolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}